Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - BofA Securities lowered its price target on Celanese (NYSE:CE) to $59.00 from $65.00 on Wednesday, while maintaining a Buy rating on the chemical company’s stock. According to InvestingPro data, the stock currently trades at 0.85 times book value and an EV/EBITDA multiple of 9.2x, suggesting potential undervaluation.
The price target reduction follows Celanese’s report of deteriorating demand and shortened order books in June and July, with limited seasonal tailwinds. The stock has faced significant pressure, with InvestingPro data showing a 67% decline over the past year and a 37% drop in the last six months. The stock had already declined over 20% from its early July peak before experiencing a 13% drop on Tuesday.
Despite these challenges, BofA Securities noted that Celanese continues to deliver on cost reductions, with Engineered Materials earnings appearing to have bottomed out alongside Asia acetyl margins. The company has also reiterated its free cash flow guidance.
BofA Securities highlighted Celanese’s progress on deleveraging and strengthening its balance sheet, including the extension of its revolving credit facility and advances on planned divestments.
The firm’s reduced price target reflects lower earnings estimates, though BofA Securities maintained its Buy recommendation, citing Celanese’s "undemanding" valuation despite recent market challenges.
In other recent news, Celanese Corporation reported its second-quarter earnings for 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $1.44, exceeding the forecasted $1.40. Revenue also surpassed predictions, reaching $2.53 billion compared to the anticipated $2.5 billion. Despite these positive earnings results, Celanese faces ongoing challenges in demand across key segments. CFRA has lowered its price target for Celanese to $30 from $37, maintaining a Sell rating due to concerns over the company’s high debt levels. These debt levels have increased during the first and second quarters of 2025. CFRA also highlighted tariff concerns and ongoing margin contraction as additional pressures on the company. These developments reflect a cautious outlook for Celanese amid the current market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.